

# **ORAL PRESENTATION**



# Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease

Daniel Sado<sup>1,2\*</sup>, Steven K White<sup>1,2</sup>, Stefan K Piechnik<sup>3</sup>, Sanjay M Banypersad<sup>1,2</sup>, Thomas A Treibel<sup>1,2</sup>, Marianna Fontana<sup>1,2</sup>, Gaby Captur<sup>1,2</sup>, Viviana Maestrini<sup>1</sup>, Robin Lachmann<sup>4,2</sup>, Derralyn Hughes<sup>5</sup>, Elaine Murphy<sup>4,2</sup>, John Porter<sup>2</sup>, Atul Mehta<sup>5</sup>, Perry Elliott<sup>1,2</sup>, James Moon<sup>1,2</sup>

*From* 16th Annual SCMR Scientific Sessions San Francisco, CA, USA. 31 January - 3 February 2013

# Background

T1 mapping is a powerful technique for ECV quantification; native T1 has been shown to increase in a variety of conditions including oedema, fibrosis and amyloid. Iron and fat lower T1. Anderson Fabry disease (AFD) is a fat storage disease, cardiac iron occurs in transfusion dependent patients. We hypothesised that T1 lowering would diagnose early cardiac involvement, track disease severity and discriminate from other mimic pathologies.

# Methods

280 subjects were studied: iron overload (n=53), AFD (n=44, 55% with LVH, all genotyped), healthy volunteers (HV, n=67, 0% with LVH), hypertension (HYP, n=41, 24% with LVH), hypertrophic cardiomyopathy (HCM, n=34, 100% with LVH), severe aortic stenosis (AS, n=21, 81% with LVH) and definite AL cardiac amyloidosis (AMY, n=20, 100% with LVH). Along with routine clinical CMR, native, non-contrast T1 mapping was performed using the Sh-MOLLI technique at 1.5T without gadolinium administration. T2\*(iron overload) and LGE and LV mass (AFD and LVH diseases) were also assessed.

#### Results

Compared to health volunteers, septal T1 was lower in iron overload and AFD and higher in other diseases (iron overload vs AFD vs healthy volunteers vs other patients,  $836\pm138$  ms,  $882\pm47$  ms,  $968\pm32$  ms,  $1018\pm74$  ms, P<0.0001).

<sup>1</sup>The Heart Hospital, London, UK

Full list of author information is available at the end of the article

In patients with LVH (n=105), T1 discriminated completely between AFD and all other diseases with no overlap (figure 1). In AFD, T1 correlated inversely with wall thickness (R=-0.51, P=0.0004) and was abnormal in 40% of subjects even without LVH. Segmentally, AFD showed pseudo-normalisation or elevation of T1 in the LV infero-lateral wall, the extent correlating with the presence or absence of post contrast late gadolinium enhancement (1001±82 ms vs 891±38 ms, P<0.0001).

In iron overload, myocardial T1 strongly correlated with T2\* (R=0.87, P<0.0001, figure 2). No patient with low T2\* had normal T1, but 25% cases characterised by a normal T2\* (n=37) had low myocardial T1 (from 2 to 5 standard deviations below normal) suggesting a quarter of patients referred have mild iron loading despite a normal T2\*.





© 2013 Sado et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.



# Conclusions

Impressive lowering of myocardial T1 can occur in AFD and particularly iron overloading. Unsuspected cardiac involvement was found in 40% of AFD patients without LVH and 25% of possible iron overload patients where T2\*was normal. When compared to the common causes of LVH, the detection of T1 lowering appears definitively diagnostic of AFD.

# Funding

- 1) British Heart Foundation.
- 2) Genzyme Pharmaceuticals.

#### Author details

<sup>1</sup>The Heart Hospital, London, UK. <sup>2</sup>University College London, London, UK. <sup>3</sup>University of Oxford, Oxford, UK. <sup>4</sup>The National Hospital for Neurology and Neurosurgery, London, UK. <sup>5</sup>Royal Free Hospital, London, UK.

Published: 30 January 2013

doi:10.1186/1532-429X-15-S1-O71

**Cite this article as:** Sado *et al.*: **Native T1 lowering in iron overload and Anderson Fabry disease; a novel and early marker of disease.** *Journal of Cardiovascular Magnetic Resonance* 2013 **15**(Suppl 1):O71.



) Bio Med Central

- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit